Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (Delaware) — Actinium Pharmaceuticals — Investor Presentation (November 2026)
36 slides from Actinium Pharmaceuticals, Inc. (Delaware)'s investor presentation, November 2026
Slide 1: Investor Presentation
Investor Presentation Pioneering Differentiated Radiotherapies for Patients with Unmet Needs November 2026 ATNM: NYSE AMERICAN
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. (“Actinium”) that are not historical facts. These forward-looking stat
Slide 3: Investment Thesis: A Novel Biology-Driven Radiotherapy Pipeline
Investment Thesis: A Novel Biology-Driven Radiotherapy Pipeline Deep understanding of disease biology shapes a differentiated radiotherapy portfolio at an inflection point with several key 2026 readouts supported by cash runway into 2028 Two Solid Tumor Assets with Pan-Cancer Blockbuster Opportuniti
Slide 4: Radiopharma Landscape: A Strategic Void Awaits Differentiated Assets
Radiopharma Landscape: A Strategic Void Awaits Differentiated Assets Innovation Gap Innovative Pipeline 6 Big 3 Targets Pharma’s Dominate industry with an acquired pipeline (PSMA, radiotherapy SSTR2 & FAP) presence $17 Billion 300,000+ In high value M&A Sq. feet of on late-stage underutilized radio
Slide 5: Actinium is Well Positioned in the Current Radio Landscape
Actinium is Well Positioned in the Current Radio Landscape A Transformative Pipeline Across Three High Value Pillars Pillar Program Differentiation & Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 ATNM-400 (HER3 Target) 5
Slide 6: Innovation Focused R&D & Manufacturing Capabilities To Drive Value
Innovation Focused R&D & Manufacturing Capabilities To Drive Value Demonstrated ability to generate novel and highly differentiated radiotherapy programs as evidenced by our highly innovative pipeline Strong In-house R&D to be Complemented Demonstrated Leading-Edge Preclinical End-to-end Supply Chai
Slide 7: Solid Tumors: ATNM-400 & Actimab-A
Solid Tumors: ATNM-400 & Actimab-A February 18, 2022 ATNM-400: First-in-class, multi-indication Ac-225 targeted radiotherapy supported by robust preclinical data in mCRPC, NSCLC & Breast Cancer Actimab-A: Potential to synergize with PD-1 and other immune checkpoint inhibitors in solid tumors by depl
Slide 8: ATNM-400: Pan Cancer Radiotherapy Targeting Blockbuster Indications
ATNM-400: Pan Cancer Radiotherapy Targeting 3 Blockbuster Indications HER3 implicated in disease biology & treatment resistance – NOT PSMA Pan-tumor potential: HER3 expressed across multiple solid tumor indications Theranostic approach with Zr-89 for imaging and Ac-225 for therapy Prostate Cancer (~
Slide 9: Blockbuster Market Opportunity for ATNM-400 in Prostate Cancer
Blockbuster Market Opportunity for ATNM-400 in Prostate Cancer Multiple near-term opportunities in non-responders and progressors with future expansion to earlier lines of treatment HSPC mHSPC mCRPC ATNM-400 Can Address Broad mCRPC Population ATNM-400 Potential Expansion in mHSPC 45 – 55K patients f
Slide 10: Transformative Therapeutic Potential of ATNM-400 for Prostate Cancer
Transformative Therapeutic Potential of ATNM-400 for Prostate Cancer Robust in vivo data show ATNM-400 achieves specific tumor uptake, decreased tumor cell proliferation, and superior efficacy versus 177Lu-PSMA-617, active agent in blockbuster radiotherapy Pluvicto ® Specific Tumor Uptake & Robust T
Slide 11: Greater Efficacy and Synergy with ARPIs Supports Large Market
Greater Efficacy and Synergy with ARPIs Supports Large Market Mechanistic rationale & data supports potential of ATNM-400 in earlier line mCRPC as a monotherapy or ARPI combination ATNM-400 Monotherapy or in Combination with ARPI Enzalutamide/XTANDI is Superior to PSMA-Targeted Agents in Prostate Ca
Slide 12: HER3 is a High-Value Target for Actinium-225 Radiotherapy in Prostate Cancer
HER3 is a High-Value Target for Actinium-225 Radiotherapy in Prostate Cancer HER3 Overexpression is Associated with Poorer Outcomes in HER3 Drives Resistance to HER3 is Ideal for 225 Ac-Targeted CRPC ARPIs in mCRPC Radiotherapy for PCa Overexpressed in Earlier progression Shorter overall Clinically
Slide 13: ATNM-400 is Efficacious Across Varying Levels of PSMA & HER3 Expression
ATNM-400 is Efficacious Across Varying Levels of PSMA & HER3 Expression In vivo efficacy in 22Rv1 prostate cancer cells In vivo efficacy in C4-2 prostate cancer cells In vivo efficacy in DU145 prostate cancer cell (Low PSMA, Moderate HER3) (High PSMA, High HER3) (Negative PSMA, Low HER3) Mean tumor
Slide 14: ATNM-400: A HER3-Targeting Radiotherapy in Prostate Cancer
ATNM-400: A HER3-Targeting Radiotherapy in Prostate Cancer Theranostic Approach • Theranostic approach with Zr-89 for imaging and Ac-225 for therapy being utilized in the Phase 1 dose escalation study in mCRPC o [89Zr]Zr-barecetamab-DFO o [225Ac]Ac-barecetamab-DOTA • HER3-positive lesions (SUV ≥1.5
Slide 15: Study Design
Study Design Key Inclusion & Imaging Assessm ent Dose Escalation Dose Expansion Exclusion Criteria & Dosimetry N=22-40 N=18 • Confirmed progressive • Theranostic-based patient • ATNM-400 IV q6w, up to 4 • ATNM-400 IV q6w, up to 4 mCRPC selection [89Zr]Zr- cycles cycles • Received at least one barece
Slide 16: Patient Summary
Patient Summary • Imaging dose (2 ± 0.2 mCi); Treatment dose (1.0 µCi/kg, 0.037 MBq/kg) Pt ATNM-400 ATNM-400 ATNM-400 ATNM-400 Age (yr) Prior Treatments HER3 +* Number (C1D1) (C2D1) (C3D1) (C4D1) ARPI 1 88 Cabazitaxel + Carboplatin ARPI Docetaxel 2 79 177 [ Lu]Lu-PSMA Cabazitaxel 3 8
Slide 17: Safety
Safety • No xerostomia • No DLTs observed • No Gr3/4 hematologic AEs observed during DLT window and beyond • No ALT/AST elevation • No Cr elevation • Gr 2 nausea (1 pt) managed with metoclopramide • No injection site or infusion-related reaction
Slide 18: Biodistribution Day 4 post [89Zr]Zr-barecetamab-DFO administration
Biodistribution Day 4 post [89Zr]Zr-barecetamab-DFO administration
Slide 19: [89Zr]Zr-barecetamab-DFO Lesion Uptake
[89Zr]Zr-barecetamab-DFO Lesion Uptake 12 D1 D4 D7 Lesion 10 SUV max SUV max SUV max 8 ROI-1 3.98 11.06 11.97 6 ROI-5 4.64 8.2 10.53 ROI-1 4 ROI-11 ROI-7 3.55 8.5 9.63 ROI-16 2 ROI-11 6.05 7.10 10.74 ROI-5 ROI-7 0 ROI-16 3.32 7.57 6.04 D1 D4 D7
Slide 20: Conclusion
Conclusion • HER3 is a compelling target for alpha therapy in mCRPC • Dose escalation of ATNM-400 has cleared dose level 1 (1 μCi/kg) with no DLTs • No xerostomia and no Gr3/4 hematologic toxicity were observed • ⁸⁹Zr-barecetamab-DFO imaging supports patient selection • PET shows encouraging tumor u
Slide 21: Acknowledgements
Acknowledgements • The Investigators and Actinium Site Location Status Genesis Care Murdoch Perth, Western Australia Enrolling Pharmaceuticals would like to ICON Cancer Centre – Hollywood Perth, Western Australia Enrolling thank all the care teams and Melbourne Theranostic Innovation Centre (MTIC) N
Slide 22: ATNM-400 Could Address NSCLC Beyond Single-Mutation Therapies
ATNM-400 Could Address NSCLC Beyond Single-Mutation Therapies Compelling preclinical data for ATNM-400 in NSCLC supported by HER3 biology, the mutation agnostic mechanism of Ac-225 and combination studies with external beam radiotherapy support backbone type of opportunity in the 2x larger than pros
Slide 23: Significant Market Expansion Opportunity Across EGFR-mutant NSCLC
Significant Market Expansion Opportunity Across EGFR-mutant NSCLC ATNM-400 outperformed 1 st, 2nd & 3 rd line approved therapies for EGFR-mutant NSCLC by 3-5x and had robust synergy in combination with 1st line osimertinib that is supported by clinical data with EBRT Osimertinib treatment increases
Slide 24: Compelling Efficacy Across All EGFR, KRAS-Mutant NSCLC Settings
Compelling Efficacy Across All EGFR, KRAS-Mutant NSCLC Settings Results Strongly Support ATNM-400’s Differentiated Profile in the Highly Competitive NSCLC Space and Potential Across 1st, 2nd & 3 rd Line Settings, Alone or In Combination with Successful Therapies Competing for Market Share • AstraZen
Slide 25: Broad Potential Demonstrated Across Multiple Breast Cancer Settings
Broad Potential Demonstrated Across Multiple Breast Cancer Settings ATNM-400’s target, HER3, is overexpressed in breast cancer including tumors resistant to endocrine therapies such as tamoxifen and HER2 targeted therapies like Herceptin ® as well as in TNBC HER2 Therapy Resistance Increases Surviva
Slide 26: Actimab-A: Tap Into the Blockbuster PD-1 Market By Depleting MDSCs
Actimab-A: Tap Into the Blockbuster PD-1 Market By Depleting MDSCs Actimab-A can be synergistic with PD-1 inhibitors by depleting MDSCs, an immune cell subtype implicated in poor response and outcomes to PD-1 inhibitors, potentially opening and expanding a $40+ billion market Clinical Data Shows Hig
Slide 27: Actimab-A MDSC + PD-1 Combination Basket Trial
Actimab-A MDSC + PD-1 Combination Basket Trial Trials supported by compelling preclinical data and mechanistic synergy will enroll patients across 4 tumor types Actimab-A targeting of MDSCs rescues Actimab-A is cytotoxic to Actimab-A homes to tumor-resident MDSCs Actimab-A depletion T cell response
Slide 28: Hematology Portfolio: AML Therapeutics & Targeted Conditioning
Hematology Portfolio: AML Therapeutics & Targeted Conditioning February 18, 2022 Actimab-A: Phase 2/3 ready, mutation agnostic Ac-225 AML therapy Iomab-B: Phase 2/3 ready BMT targeted conditioning agent Iomab-ACT: Potential universal conditioning to improve access and outcomes for cell & gene therap
Slide 29: Heme Assets - Potential to Transform the AML & MDS Treatment Journey
Heme Assets - Potential to Transform the AML & MDS Treatment Journey Late-stage differentiated radio assets have strong synergy with favorable commercial dynamics and can address the unmet needs of 110,000 patients in the U.S. and EU Iomab-B BMT Conditioning: R/R AML Phase 2/3 Therapy BMT Post-BMT I
Slide 30: Actimab-A: Universal AML Backbone, De-Risked and Partner-Ready
Actimab-A: Universal AML Backbone, De-Risked and Partner-Ready Only CD33 targeting clinical stage radiotherapy supported by strong data and Actimab-A NCI CRADA Actimab-A: AML & MDS Therapeutics • Mutation agnostic Ac-225 backbone therapy with strong data in high-risk patients • Aligned with the FDA
Slide 31: Actimab-A + CLAG-M: Results Support Phase 2/3 Trial in R/R AML
Actimab-A + CLAG-M: Results Support Phase 2/3 Trial in R/R AML High Rates of MRD Negativity and Improved Phase 2/3 Trial to Enroll Patients with 1 st or 2nd Salvage Survival Outcomes in High-Risk R/R Patients1 R/R AML, Group Had Best Outcomes in Phase 1b Trial • 24-month median overall survival in t
Slide 32: Iomab-B/ACT: Targeted Conditioning to Unlock BMT, Cell & Gene Therapy
Iomab-B/ACT: Targeted Conditioning to Unlock BMT, Cell & Gene Therapy Only CD45-targeted conditioning radiotherapy in development — de-risked by SIERRA and 500+ patients treated Iomab-B and Iomab-ACT: Targeted Conditioning, A Gateway to Curative Therapies • Two CD45 targeted radiotherapies designed
Slide 33: Iomab-ACT Further Expands Heme Portfolio Market Opportunity
Iomab-ACT Further Expands Heme Portfolio Market Opportunity BMT & Gene Therapy Conditioning – Commercial CAR-T Phase 1B/2 Trial Sickle Cell Disease BMT Phase 1 Trial Enrollment Enrollment N = 30 patients N = 24 patients (single arm) PRIMARY SECONDARY PRIMARY & SECONDARY OBJECTIVES OBJECTIVES OBJECTI
Slide 34: 2026-2027 Outlook & Milestones
2026-2027 Outlook & Milestones February 18, 2022 Transformational period with multiple first-in-class therapies reaching inflection points supporting our vision to be a leading fully-integrated targeted radiotherapy company ATNM: NYSE AMERICAN
Slide 35: 2026-2027: A Period of Transformational Milestones and Data Readouts
2026-2027: A Period of Transformational Milestones and Data Readouts 4Q:26 Target disclosed at a medical conference 4Q:26 Demonstration of pan cancer potential 4Q:26 Host KOL webinar ATNM-400 4Q:26 Initial biodistribution and safety data in prostate cancer 2027 Translational data in additional indic
Slide 36: Thank You
Thank You Actinium Pharmaceuticals, Inc. ATNM: NYSE AMERICAN
Actinium Pharmaceuticals — Investor Presentation (November 2026) on 6ix